Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AMPH

AMPH - Amphastar Pharmaceuticals Inc Stock Price, Fair Value and News

40.05USD-0.49 (-1.21%)Market Closed

Market Summary

AMPH
USD40.05-0.49
Market Closed
-1.21%

AMPH Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)

AMPH Stock Price

View Fullscreen

AMPH RSI Chart

AMPH Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

12.66

Price/Sales (Trailing)

2.9

EV/EBITDA

9.53

Price/Free Cashflow

12.17

AMPH Price/Sales (Trailing)

AMPH Profitability

Operating Margin

54.33%

EBT Margin

27.46%

Return on Equity

23.01%

Return on Assets

9.83%

Free Cashflow Yield

8.22%

AMPH Fundamentals

AMPH Revenue

Revenue (TTM)

676.2M

Rev. Growth (Yr)

22.72%

Rev. Growth (Qtr)

-3.52%

AMPH Earnings

Earnings (TTM)

154.7M

Earnings Growth (Yr)

65.86%

Earnings Growth (Qtr)

19.38%

Breaking Down AMPH Revenue

Last 7 days

-2.6%

Last 30 days

-7.9%

Last 90 days

-9.0%

Trailing 12 Months

-27.2%

How does AMPH drawdown profile look like?

AMPH Financial Health

Current Ratio

2.18

Debt/Equity

0.88

Debt/Cashflow

0.33

AMPH Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

2.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024676.2M000
2023518.6M540.9M601.3M644.4M
2022455.1M476.9M484.9M499.0M
2021368.2M384.0M412.8M437.8M
2020327.3M334.0M337.3M349.8M
2019316.1M324.1M328.7M322.4M
2018241.9M247.8M265.4M294.7M
2017252.5M249.6M243.3M240.2M
2016254.0M268.2M268.5M255.2M
2015221.5M226.3M230.5M251.5M
2014222.6M209.1M209.5M210.5M
2013210.7M217.0M223.3M229.7M
2012000204.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amphastar Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
petersen floyd f.
sold
-124,200
41.4
-3,000
-
Jun 10, 2024
zhang jack y.
acquired
1,469,000
14.69
100,000
ceo & chief scientific officer
Jun 05, 2024
lee howard
sold (taxes)
-24,341
42.04
-579
-
Jun 04, 2024
liawatidewi yakob
sold (taxes)
-11,483
42.22
-272
evp corp admin center
Jun 03, 2024
zasloff michael a
acquired
-
-
3,076
-
Jun 03, 2024
lee howard
acquired
-
-
3,076
-
Jun 03, 2024
petersen floyd f.
sold
-21,325
42.6518
-500
-
Jun 03, 2024
gerst diane g.
acquired
-
-
3,076
-
Jun 03, 2024
deflin gayle
acquired
-
-
3,076
-
Jun 03, 2024
petersen floyd f.
acquired
-
-
3,076
-

1–10 of 50

Which funds bought or sold AMPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-3,711
-
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-397,000
892,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-209,000
514,000
-%
May 24, 2024
Invst, LLC
new
-
251,127
251,127
0.03%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.84
62,992
405,992
0.05%
May 20, 2024
CIM, LLC
added
0.76
-70,886
409,022
0.06%
May 20, 2024
EMC Capital Management
new
-
137,000
137,000
0.08%
May 17, 2024
VIMA LLC
sold off
-100
-17,936
-
-%
May 16, 2024
COMERICA BANK
reduced
-7.03
-352,623
684,601
-%
May 16, 2024
HANCOCK WHITNEY CORP
added
58.42
29,727
268,160
0.01%

1–10 of 48

Are Funds Buying or Selling AMPH?

Are funds buying AMPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMPH
No. of Funds

Unveiling Amphastar Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 06, 2024
federated hermes, inc.
4.52%
2,165,071
SC 13G/A
Feb 13, 2024
vanguard group inc
5.88%
2,814,710
SC 13G/A
Feb 09, 2024
zhang jack y.
26.2%
13,435,210
SC 13G/A
Jan 23, 2024
blackrock inc.
12.6%
6,037,158
SC 13G/A
Jan 17, 2024
federated hermes, inc.
6.83%
3,272,761
SC 13G/A
Feb 09, 2023
vanguard group inc
5.42%
2,621,807
SC 13G/A
Feb 01, 2023
federated hermes, inc.
6.80%
3,284,217
SC 13G/A
Jan 27, 2023
zhang jack y.
25.5%
13,110,695
SC 13G/A
Jan 26, 2023
blackrock inc.
14.6%
7,038,769
SC 13G/A
Jan 20, 2023
blackrock inc.
14.6%
7,038,769
SC 13G/A

Recent SEC filings of Amphastar Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading

Peers (Alternatives to Amphastar Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.5B
85.6B
-5.78% -11.28%
9.11
4.09
5.68% 202.39%
324.2B
61.4B
-2.40% 17.12%
140.58
5.28
6.11% -82.30%
164.1B
29.5B
-2.07% 33.24%
43.62
5.56
12.76% -52.47%
155.3B
35.0B
-4.26% -31.55%
133.67
4.43
-26.40% -92.03%
78.7B
27.4B
-6.75% -19.92%
162.39
2.87
1.51% -91.32%
19.1B
16.0B
4.36% 125.46%
-38.63
1.19
7.23% 71.10%
MID-CAP
4.1B
1.7B
1.12% -24.14%
9.51
2.39
54.01% 364.56%
3.5B
4.6B
-14.38% -25.76%
-452.34
0.76
-0.06% 94.55%
2.4B
9.0B
-4.43% -11.97%
-5.22
0.26
10.01% -27.45%
2.0B
676.2M
-7.89% -27.22%
12.66
2.9
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-14.65% 8.33%
-3.72
1.76
24.65% 80.36%
21.5M
1.3M
-16.22% -51.69%
-2.9
16.47
-98.14% -104.71%
13.3M
89.6M
-27.78% -33.90%
-0.93
0.19
287.27% -129.41%
2.3M
21.5M
-10.53% -89.57%
-0.3
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Amphastar Pharmaceuticals Inc News

Latest updates
Simply Wall St17 Jun 202403:48 pm
StockNews.com15 Jun 202401:10 pm
Seeking Alpha15 May 202407:00 am
Investor's Business Daily4 months ago

Amphastar Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-3.5%17217818114614013512012312012111210210396.0083.0086.0085.0083.0080.0079.0080.00
Cost Of Revenue-0.3%82.0082.0072.0073.0066.0064.0062.0060.0065.0065.0061.0054.0058.0059.0047.0053.0048.0050.0045.0047.0049.00
Gross Profit-6.3%90.0096.0010873.0074.0071.0059.0063.0056.0056.0051.0047.0045.0037.0037.0033.0037.0033.0035.0032.0031.00
Operating Expenses-0.2%42.0042.0036.0036.0040.0033.0035.0039.0034.0032.0026.0037.0035.0034.0033.0036.0029.0034.0033.0031.0034.00
  S&GA Expenses8.7%9.009.006.007.007.005.005.006.006.004.005.004.005.004.004.004.003.003.003.003.003.00
  R&D Expenses-16.5%17.0020.0017.0017.0020.0017.0019.0023.0016.0017.0011.0018.0015.0018.0018.0016.0015.0020.0019.0016.0015.00
EBITDA Margin5.1%0.36*0.35*0.36*0.30*0.28*0.28*0.26*0.29*0.29*0.24*0.18*0.11*---------
Interest Expenses-8.9%9.009.0014.004.000.001.001.000.000.000.001.000.000.000.000.000.000.000.000.000.000.00
Income Taxes-11.7%4.005.0014.006.007.007.007.006.004.007.007.006.001.00-0.952.00-0.072.000.001.0014.00-1.48
Earnings Before Taxes15.8%48.0041.0064.0033.0034.0041.0023.0023.0029.0027.0038.0014.005.00-6.747.00-1.506.001.002.0061.00-3.63
EBT Margin3.3%0.27*0.27*0.28*0.24*0.23*0.23*0.21*0.25*0.24*0.19*0.12*0.05*---------
Net Income19.4%43.0036.0049.0026.0026.0034.0016.0017.0024.0020.0030.008.005.00-6.274.00-0.194.00-1.031.0048.001.00
Net Income Margin7.2%0.23*0.21*0.22*0.19*0.18*0.18*0.16*0.19*0.18*0.14*0.09*0.03*---------
Free Cashflow222.4%46.0014.0054.0046.0031.009.0015.00-3.1545.0034.00-4.6526.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.1%1,5741,5131,5451,378774742727724716672652666646631614600573587586601545
  Current Assets13.4%555490543385408378384377364318304311300280277267247255269284230
    Cash Equivalents39.4%20114426714917715615716617312710712510295.0090.0089.0057.0076.0087.0012281.00
  Inventory9.1%11510611010510410410399.0095.0093.0010098.0097.0097.0010910510811111099.0079.00
  Net PPE2.0%289283281279243238233238243244243253253260246238231234222220215
Liabilities3.3%902873949789225213222224237226222199195183163158149159152169164
  Current Liabilities13.2%25522525825110695.0010210411410498.0012512711297.0093.0083.0090.0087.00101112
  Long Term Debt0.8%59459063848873.0073.0074.0074.0074.0075.0076.0030.0032.0034.0033.0035.0036.0039.0038.0040.0031.00
Shareholder's Equity5.2%672639595589549529505499480446430467451449451442423428434432380
  Retained Earnings10.5%45240937332429827223822220518016113112311812412012011611711668.00
  Additional Paid-In Capital-2.1%476486478471457455449443433422413427414410404397371367362355349
Shares Outstanding1.6%49.0048.0048.0049.0048.0048.0049.0049.0048.0048.0048.0048.00---------
Minority Interest------------45.0045.0046.0046.0045.0046.0046.0044.0044.0045.00
Float----1,487---885---482---567---638-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations131.7%55,29123,86464,33454,92340,38215,22620,3752,81550,76540,4412,56932,15922,82516,8938,80730,0891,4775,652-12,00351,723-3,610
  Share Based Compensation59.2%7,3604,6224,6444,8656,1114,3044,2994,2355,0223,8503,9196,0844,8344,3334,3706,5135,2824,2954,2944,0324,674
Cashflow From Investing114.8%15,237-103,049-31,152-508,582-6,333-229-15,258-8,180-9,110-11,954-3,769-4,254-8,695-12,176-5,451-10,066-8,722-7,352-18,622-9,669-14,884
Cashflow From Financing71.2%-13,579-47,08386,613428,111-13,548-16,162-13,931-9944,648-8,696-16,492-5,191-6,639-227-3,02612,456-11,449-10,382-3,888-74211,229
  Buy Backs---50,0011288,01518,06914,4946,1171,22913,4366,0935,5613,7833,3904,3295,75610,95013,7774,4261,0733,015
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AMPH Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Net Revenues:  
Total net revenues$ 171,836$ 140,022
Cost of revenues81,73666,182
Gross profit90,10073,840
Operating expenses:  
Selling, distribution, and marketing9,3717,109
General and administrative15,67613,483
Research and development17,04319,815
Total operating expenses42,09040,407
Income from operations48,01033,433
Non-operating income (expenses):  
Interest income2,556924
Interest expense(8,611)(398)
Other income (expenses), net5,921(390)
Total non-operating income (expenses), net(134)136
Income before income taxes47,87633,569
Income tax provision4,1266,752
Income before equity in losses of unconsolidated affiliate43,75026,817
Equity in losses of unconsolidated affiliates(573)(785)
Net income attributable to Amphastar Pharmaceuticals, Inc.43,17726,032
Net income attributable to Amphastar Pharmaceuticals, Inc.$ 43,177$ 26,032
Net income per share  
Basic (in Dollars per share)$ 0.90$ 0.54
Diluted (in Dollars per share)$ 0.81$ 0.50
Weighted-average shares used to compute net income per shares  
Basic (in Shares)48,21248,000
Diluted (in Shares)53,01351,970
Product revenues, net  
Net Revenues:  
Total net revenues$ 157,629$ 140,022
Other revenues  
Net Revenues:  
Total net revenues$ 14,207 

AMPH Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 201,148$ 144,296
Restricted cash235235
Short-term investments88,407112,510
Restricted short-term investments2,2002,200
Accounts receivable, net138,114114,943
Inventories115,494105,833
Income tax refunds and deposits784526
Prepaid expenses and other assets8,6969,057
Total current assets555,078489,600
Property, plant, and equipment, net288,523282,746
Finance lease right-of-use assets516564
Operating lease right-of-use assets31,35232,333
Investment in unconsolidated affiliate 527
Goodwill and intangible assets, net607,064613,295
Long-term investments15,16314,685
Other assets23,36925,910
Deferred tax assets53,25253,252
Total assets1,574,3171,512,912
Current liabilities:  
Accounts payable and accrued liabilities116,69793,366
Accrued payments for BAQSIMI128,245126,090
Income taxes payable5,8571,609
Current portion of long-term debt428436
Current portion of operating lease liabilities3,9423,906
Total current liabilities255,169225,407
Long-term reserve for income tax liabilities6,0666,066
Long-term debt, net of current portion and unamortized debt issuance costs594,006589,579
Long-term operating lease liabilities, net of current portion28,73929,721
Other long-term liabilities17,98122,718
Total liabilities901,961873,491
Commitments and Contingencies
Stockholders' equity:  
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock: par value $0.0001; 300,000,000 shares authorized; 60,160,459 and 48,841,343 shares issued and outstanding as of March 31, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding as of December 31, 2023, respectively66
Additional paid-in capital476,072486,056
Retained earnings452,445409,268
Accumulated other comprehensive loss(8,769)(8,478)
Treasury stock(247,398)(247,431)
Total equity672,356639,421
Total liabilities and stockholders' equity$ 1,574,317$ 1,512,912
AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
 CEO
 WEBSITEamphastar.com
 INDUSTRYPharmaceuticals
 EMPLOYEES1615

Amphastar Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Amphastar Pharmaceuticals Inc? What does AMPH stand for in stocks?

AMPH is the stock ticker symbol of Amphastar Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amphastar Pharmaceuticals Inc (AMPH)?

As of Tue Jun 18 2024, market cap of Amphastar Pharmaceuticals Inc is 1.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers. The fair value of Amphastar Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amphastar Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amphastar Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMPH is over valued or under valued. Whether Amphastar Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amphastar Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMPH.

What is Amphastar Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, AMPH's PE ratio (Price to Earnings) is 12.66 and Price to Sales (PS) ratio is 2.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMPH PE ratio will change depending on the future growth rate expectations of investors.